NASDAQ:IMDX Oncocyte 5/13/2026 Earnings Report $5.35 +0.25 (+4.96%) As of 11:00 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Oncocyte EPS ResultsActual EPS-$0.28Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOncocyte Revenue ResultsActual Revenue$0.03 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOncocyte Announcement DetailsQuarterDate5/13/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Oncocyte Earnings HeadlinesInsight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings Call TranscriptMay 13 at 9:03 PM | seekingalpha.comIMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure CommercializationMay 13 at 4:05 PM | globenewswire.comPeptide Company Lands Exclusive MMA Wellness PartnershipA publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform tied to Conor McGregor and Dana White - reaching millions of combat sports and biohacking followers worldwide. On April 15, RFK Jr. announced the FDA would remove 12 peptides from restricted Category 2 status. This company was already selling products tied to three of those peptides - and has developed a patent-pending transdermal patch addressing the 63.2% of adults with needle phobia. The peptide therapeutics market is projected to reach $294 billion by 2033.May 14 at 1:00 AM | The Tomorrow Investor (Ad)iMDx to Release First Quarter 2026 Results on May 13, 2026May 6, 2026 | globenewswire.comReal-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure AssayApril 14, 2026 | globenewswire.comInsight Molecular Diagnostics Inc. (IMDX) Q4 2025 Earnings Call TranscriptMarch 26, 2026 | seekingalpha.comSee More Oncocyte Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oncocyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncocyte and other key companies, straight to your email. Email Address About OncocyteOncocyte (NASDAQ:IMDX) (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges. Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows. Its offerings are positioned to support physicians by reducing diagnostic uncertainty, guiding the need for invasive procedures, and helping to prioritize patients for additional testing or treatment. The company pursues clinical validation and regulatory review as part of its path to broader commercial adoption. Headquartered in the United States, Oncocyte distributes its tests through clinical laboratory networks and strategic partnerships aimed at reaching physicians and healthcare systems. As a publicly listed company on the NASDAQ (IMDX), it concentrates on advancing its diagnostic pipeline, expanding commercial operations, and engaging with payors and clinical stakeholders to integrate its assays into standard oncology care pathways. Information on individual executives and recent leadership changes should be confirmed from the company’s filings and official communications for the most current details.View Oncocyte ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nebius Upside Expands as AI Feedback Loop IntensifiesOklo Stock Could Be Ready for Another Massive RunD-Wave Earnings Looked Weak, But Investors May Be Missing ThisChime Finally Turns Profitable—But Risks RemainHow Berkshire’s New York Times Bet Looks TodayPlug Power Flips The Switch On ProfitabilityHims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery? Upcoming Earnings Mizuho Financial Group (5/15/2026)Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
